Description
BSE lists 4,00,000 new equity shares of Novelix Pharmaceuticals Limited issued on a preferential basis pursuant to conversion of warrants, effective March 9, 2026.
Summary
BSE has listed 4,00,000 new equity shares of Novelix Pharmaceuticals Limited (Scrip Code: 536565) issued to non-promoters on a preferential basis through conversion of warrants. These shares are permitted to trade on the Exchange effective Monday, March 9, 2026.
Key Points
- 4,00,000 equity shares of Rs. 10/- each issued at a premium of Rs. 10/- (issue price Rs. 20/-)
- Issued to non-promoters on a preferential basis pursuant to conversion of warrants
- New shares rank pari-passu with existing equity shares
- Distribution numbers: 17215001 to 17615000
- ISIN: INE314I01036
- Date of allotment: January 19, 2026
Regulatory Changes
No new regulatory changes. This is a standard listing notification following completion of a preferential allotment process under existing SEBI and BSE regulations.
Compliance Requirements
- Trading members are informed that the new securities are now listed and permitted to trade from March 9, 2026
- Lock-in applies to all 4,00,000 shares (Dist. Nos. 17215001 to 17615000) until September 30, 2026
Important Dates
- Date of Allotment: January 19, 2026
- Trading commencement: March 9, 2026 (Monday)
- Lock-in expiry: September 30, 2026
Impact Assessment
The listing adds 4,00,000 new equity shares to Novelix Pharmaceuticals Limited’s capital base at an issue price of Rs. 20/- per share. Since all newly listed shares are under lock-in until September 30, 2026, there is no immediate free-float impact. Market impact is minimal given the small share count relative to typical trading volumes.
Impact Justification
Routine listing of new equity shares from preferential allotment via warrant conversion for a small-cap company; limited broader market impact.